Log In
Print
BCIQ
Print
Print this Print this
 

Cambia, diclofenac (PRO-513)

  Manage Alerts
Collapse Summary General Information
Company Nautilus Neurosciences Inc.
DescriptionOral formulation of diclofenac potassium powder using Dynamic Buffering Technology (DBT)
Molecular Target Cyclooxygenases (COX)
Mechanism of ActionNSAID
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat migraine
Regulatory Designation
Partner Applied Pharma Research S.A.; Depomed Inc.; Tribute Pharmaceuticals Canada Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

6

$1,999.7M

$1,848.7M

$5.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today